At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 158 enrolled
Drug / intervention
Radezolid +2 moredrug
Likely dose
Radezolid 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP)
In Brief
A Phase 2 clinical trial evaluating Radezolid for Community-Acquired Pneumonia (CAP). Completed, enrolled 158 participants across 30 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-Acquired Pneumonia (CAP)
CountriesCanada, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedMar 2008
Primary CompletionMar 2009
Study CompletionApr 2009
TodayJul 2026
First PostedMar 21, 2008
Enrollment StartOct 1, 2007
Primary CompletionMar 1, 2009
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.3 years ago
Interventions
Radezoliddrug
300 mg/day, orally for 7-10 days
Radezoliddrug
450 mg/day orally for 7-10 days
Radezoliddrug
900 mg/day orally for 7-10 days